Literature DB >> 7504917

Targeted inhibition of immunodeficiency virus replication in lymphocytes through retroviral mediated gene transfer.

F Y Tung1, M D Daniel.   

Abstract

To test the feasibility of gene therapy for AIDS patients, an animal model is needed to evaluate the efficacy and safety of this approach. Antiviral genes (encoding antisense RNA or viral protein) derived from Simian immunodeficiency virus (SIV) were efficiently targeted into CD4+ lymphocytes through retroviral-mediated gene transfer. After challenging with infectious viruses, the transduced lymphocytes that received antiviral genes were not only protected from SIV infection, but also from infection with HIV, for at least 25 days. Furthermore, little or no cytolytic effect (syncytium formation) was observed in the protected cells. These data demonstrated that SIV or HIV replication could be effectively blocked by antisense sequence(s) or negative dominant factors which were introduced into targeted cells through retroviral-mediated gene transfer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504917      PMCID: PMC7086800          DOI: 10.1007/bf01313779

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  33 in total

1.  The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus.

Authors:  D A Regier; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

2.  Differential ability of human immunodeficiency virus isolates to productively infect human cells.

Authors:  L A Evans; T M McHugh; D P Stites; J A Levy
Journal:  J Immunol       Date:  1987-05-15       Impact factor: 5.422

3.  Construction and applications of a highly transmissible murine retrovirus shuttle vector.

Authors:  C L Cepko; B E Roberts; R C Mulligan
Journal:  Cell       Date:  1984-07       Impact factor: 41.582

4.  Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

Authors:  S A Rosenberg; P Aebersold; K Cornetta; A Kasid; R A Morgan; R Moen; E M Karson; M T Lotze; J C Yang; S L Topalian
Journal:  N Engl J Med       Date:  1990-08-30       Impact factor: 91.245

5.  Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac.

Authors:  Y M Naidu; H W Kestler; Y Li; C V Butler; D P Silva; D K Schmidt; C D Troup; P K Sehgal; P Sonigo; M D Daniel
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

6.  Vaccine protection against simian immunodeficiency virus infection.

Authors:  R C Desrosiers; M S Wyand; T Kodama; D J Ringler; L O Arthur; P K Sehgal; N L Letvin; N W King; M D Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  A formalin-inactivated whole SIV vaccine confers protection in macaques.

Authors:  M Murphey-Corb; L N Martin; B Davison-Fairburn; R C Montelaro; M Miller; M West; S Ohkawa; G B Baskin; J Y Zhang; S D Putney
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

8.  Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA.

Authors:  G Sczakiel; M Pawlita
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

9.  Inhibition of human immunodeficiency virus type 1 multiplication by antisense and sense RNA expression.

Authors:  S Joshi; A Van Brunschot; S Asad; I van der Elst; S E Read; A Bernstein
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

10.  Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis.

Authors:  G Sczakiel; M Oppenländer; K Rittner; M Pawlita
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

View more
  2 in total

Review 1.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

2.  Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication.

Authors:  G Veres; U Junker; J Baker; C Barske; C Kalfoglou; H Ilves; S Escaich; H Kaneshima; E Böhnlein
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.